Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
Primary Phase I:To determine dose limiting toxicities and maximum tolerated dose (MTD) of the oral administration of hydroxychloroquine (HCQ) in conjunction with transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC). A conventional 3+3 design will be utilized. Primary Phase II: To evaluate the complete response rate in a cohort of patients treated at the MTD, A Simon\'s Optimal Two-stage design will be utilized.
Epistemonikos ID: 5a9d8c25f49971b3b095eb1172f516d0f12a64ab
First added on: May 11, 2024